Form 4: Phio Pharmaceuticals Corp. Insider Buys Shares

Robert J. Bitterman, Director and CEO of Phio Pharmaceuticals Corp., acquired 10,000 shares of common stock on June 26, 2026.

Summary

• Robert J. Bitterman, who holds the positions of Director, Chairman, President, and CEO at Phio Pharmaceuticals Corp., purchased 10,000 shares of the company's common stock.
• The transaction occurred on June 26, 2026, with the shares acquired at a price of $0.99 per share.
• Following this acquisition, Mr. Bitterman beneficially owns a total of 421,421 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing due to the significant share acquisition by a key executive, signaling confidence in the company's value.

Positives

• Insider purchase of 10,000 shares by a key executive (CEO, Chairman, President, Director) signals confidence in the company's future prospects.
• The acquisition price of $0.99 per share suggests a potentially undervalued stock or a belief in its appreciation from current levels.
• The reporting person, Robert J. Bitterman, already holds a significant number of shares (421,421), indicating a substantial personal investment in the company.

Negatives

• The filing is a Form 4, which reports a single transaction by an insider and does not provide broader financial performance data or company outlook.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by C-suite executives and directors, are often viewed positively by the market as they can indicate strong conviction in the company's intrinsic value and future growth potential. This is especially relevant in the biopharmaceutical sector where significant milestones and funding rounds can heavily influence stock performance.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing confidence in the company's management and future performance.
• Employees may be encouraged by the visible commitment of their CEO and other leaders to the company's success.
• Creditors and suppliers may see this as a sign of stability and continued operational viability.

Key Dates

Recommendation

While an insider purchase is a positive signal, a Form 4 filing alone does not provide sufficient financial or strategic information to warrant a strong buy or sell recommendation. It suggests management confidence but requires further analysis of the company's overall financial health and strategic direction.

Keywords

Phio Pharmaceuticals Corp., PHIO, Form 4, Insider Trading, Stock Acquisition, Beneficial Ownership, Robert J. Bitterman, SEC Filing